Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;21(12):1474-1490.
doi: 10.1038/s41423-024-01229-8. Epub 2024 Oct 28.

Glut3 promotes cellular O-GlcNAcylation as a distinctive tumor-supportive feature in Treg cells

Affiliations

Glut3 promotes cellular O-GlcNAcylation as a distinctive tumor-supportive feature in Treg cells

Amit Sharma et al. Cell Mol Immunol. 2024 Dec.

Abstract

Regulatory T cells (Tregs) establish dominant immune tolerance but obstruct tumor immune surveillance, warranting context-specific mechanistic insights into the functions of tumor-infiltrating Tregs (TIL-Tregs). We show that enhanced posttranslational O-linked N-acetylglucosamine modification (O-GlcNAcylation) of cellular factors is a molecular feature that promotes a tumor-specific gene expression signature and distinguishes TIL-Tregs from their systemic counterparts. We found that altered glucose utilization through the glucose transporter Glut3 is a major facilitator of this process. Treg-specific deletion of Glut3 abrogates tumor immune tolerance, while steady-state immune homeostasis remains largely unaffected in mice. Furthermore, by employing mouse tumor models and human clinical data, we identified the NF-κB subunit c-Rel as one such factor that, through Glut3-dependent O-GlcNAcylation, functionally orchestrates gene expression in Tregs at tumor sites. Together, these results not only identify immunometabolic alterations and molecular events contributing to fundamental aspects of Treg biology, specifically at tumor sites but also reveal tumor-specific cellular properties that can aid in the development of Treg-targeted cancer immunotherapies.

Keywords: Glut3; O-GlcNAcylation; Regulatory T cells; Treg; Treg metabolism.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Garima Sharma is an employee of ImmunoBiome Inc, South Korea. SHI is the founder and major shareholder of ImmunoBiome Inc, South Korea. SML is an employee of Lipidall Technologies Company Limited, China. The authors have no conflicting financial interests.

References

    1. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012;30:531–64. - PMC - PubMed
    1. Tanaka A, Sakaguchi S. Targeting Treg cells in cancer immunotherapy. Eur J Immunol. 2019;49:1140–6. - PubMed
    1. Liu C, Chikina M, Deshpande R, Menk AV, Wang T, Tabib T, et al. Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8(+) T-Cell-Derived Interferon-gamma. Immunity. 2019;51:381–97.e6. - PMC - PubMed
    1. Bos P, Rudensky A. Transient regulatory T-cell ablation deters oncogene driven breast cancer and enhances radiotherapy. J Exp Med. 2013;210:2435–46. - PMC - PubMed
    1. Klages K, Mayer CT, Lahl K, Loddenkemper C, Teng MW, Ngiow SF, et al. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res. 2010;70:7788–99. - PubMed

LinkOut - more resources